Mental Health Blog


Bipolar Disorder Explained in ASL

Posted in Bipolar Disorder by on the April 16, 2014
Tags: , ,

0

Is bipolar just mood swings? What does it feel like to have bipolar? What’s the difference between Bipolar I and Bipolar II? Who diagnoses it? How is it trea…
Video Rating: 5 / 5

Group Counseling –Leadership Skills I–Impact Therapy

Posted in Counseling by on the April 15, 2014
Tags: , , , , ,

0

Drs. Chris Schimmel and Ed Jacobs discuss group leadership skills based on their book Group Counseling: Strategies and Skills and Impact Therapy.

Mental Health Treatment and Addiction Care Expands Under New Obama Administration Rules

Posted in Bipolar Disorder by on the April 14, 2014
Tags: , , , , , , , , ,

0

Fort Lauderdale, Fla. (PRWEB) November 26, 2013

Out with the old and in with the new. After more than five years of waiting for the final rule on the Mental Health Parity and Addiction Equity Act, the results are in, and its good news according to the Sylvia Brafman Mental Health Center.

Were pleased to see that the Parity Act has finally been put into effect, said Ben Brafman, the founder and CEO of the Sylvia Brafman Mental Health Center. The final ruling ensures that mental health and addiction must be treated on par with physical and surgical health services. In the past, that wasnt always the case.

Insurance companies are now required to provide equal benefits and coverage for addiction and mental health as they do for other medical coverage. This is known as parity, and according to experts it is a big achievement for mental health treatment. The law applies to everyone covered under health policies offered by their employers, group plans, and the health insurance marketplace. Medicare and Medicaid are not affected.

Prior to parity, clients with a mental health disorder or addiction were extremely restricted as far as access to treatment, said Brafman, a 20-year veteran of the behavioral health industry. Insurers used to be able to deny coverage based on mental illness, and in effect that translated to denying mental health treatment to those who need it most. They cant do that anymore.

Any limitations on coverage must now be disclosed by insurers, including the standards used to determine limitations. Intensive outpatient treatment and residential treatment are also protected by the parity act, meaning that clients arent obligated to pay for their own accommodation during treatment. This is a first-time addition to insurance coverage, and establishes fair treatment between mental and medical services.

Although the new ruling expands mental health treatment, it does not necessarily open the floodgates for everyone, explained behavioral health expert Brafman. The law doesnt require insurers to cover all levels of treatment. It only stipulates that if they provide a certain level of treatment for physical health, they must do the same for mental health.

This expansion of care appears to be a step in the right direction for cutting down the stigma associated with addiction and mental illness. The final rule will be implemented from July 2014, although we may not see its full effects until the beginning of the following year.

####

The Sylvia Brafman Mental Health Center is a full service mental health facility located in Fort Lauderdale, Fla. Dedicated to helping individuals who suffer from mental illness find a path to living better, The Sylvia Brafman Mental Health Center offers a mental health program and support for a wide variety of mood and thought disorders including: depression, anxiety disorders, anger management, eating disorders, post-traumatic stress disorder (PTSD), bipolar disorder, schizophrenia and schizoaffective disorder. For more information on mental health treatment please contact The Sylvia Brafman Mental Health Center at 1-888-205-2775 or online at http://www.mentalhealthcenter.org.







Related Bipolar Disorder Press Releases

DrugNews Announces Launch of Topamax Resource Center for Birth Defects

Posted in Bipolar Disorder by on the April 13, 2014
Tags: , , , , , , ,

0

Dallas, TX (PRWEB) December 02, 2013

The DrugNews.net prescription drug safety center is announcing the launch of a new resource for patients taking the antiepileptic drug Topamax. The site will contain studies on birth defect side effects, safety alerts for patients, as well as legal news for any birth defect claims.

DrugNews is a resource site for those taking popular prescription drugs. By sharing the latest medication recalls, safety alerts, research and litigation news, patients can avoid dangerous drugs, see if others are experiencing similar side effects and decide if they need legal advice.

Topamax is an epileptic drug manufactured by Johnson & Johnson that is prescribed for epilepsy, seizures, Lennox-Gastaut syndrome, bipolar disorder, migraine headaches and weight gain.

Unfortunately, experts have warned the drug may increase the risk of birth defects. The resource center has added an FDA warning that infants born to women taking Topamax during pregnancy may have a higher risk of cleft lip and/or cleft palate*.

Also, DrugNews has added a study from the United Kingdom suggesting the rate of birth defects like cleft lip and cleft palate is 11 times that of normal for children exposed to Topamax during pregnancy**.

So far, more than 130 families have filed a Topamax lawsuit alleging birth defects from the drug in a special court. The formal case is known as In re Topamax Litigation, 110602131, Court of Common Pleas, Philadelphia County, Pennsylvania.

Now, DrugNews has learned that a jury awarded one family $ 4 million*** and another $ 11 million**** in recent months in the first two trials over Topamax birth defects.

Anyone with a child affected by birth defects after taking Topamax is urged to visit DrugNews.net or speak with a lawyer about their legal options. However, due to the specialized nature of drug injury cases, DrugNews only recommends lawyers who have already handled Topamax lawsuits.

Visit http://www.DrugNews.net today for more information on the research, side effects and litigation news related to Topamax and other drugs, or to speak with a lawyer.

*FDA 3/4/11; http://www.fda.gov/Drugs/DrugSafety/ucm245085.htm

**Neurology, March 2008; neurology.org/content/71/4/272

***10/30/13, April Czimmer, et al. v. Ortho-McNeil-Janssen Pharmaceutica, No. 1105-03459, Pa. Comm. Pls., Philadelphia Co.; lexisnexis.com/legalnewsroom/litigation/b/litigation-blog/archive/2013/10/31/4-million-awarded-in-1st-pa-trial-alleging-birth-defect-from-topamax-epilepsy-drug.aspx

****11/18/13, Gurley v. Ortho-McNeil-Janssen Pharmaceutical, 110502251, Court of Common Pleas, Philadelphia County, Pennsylvania; bloomberg.com/news/2013-11-18/j-j-s-janssen-loses-11-million-jury-verdict-over-topamax.html







Find More Bipolar Disorder Press Releases

RMACT to Host a Series of Fertility Seminars That Include Fertility Testing

Posted in Counseling by on the April 12, 2014
Tags: , , , , , ,

0

Stamford, CT (PRWEB) April 08, 2014

Reproductive Medicine Associates of Connecticut (RMACT) is offering free anti-mullerian hormone (AMH) tests for women who want to know more about their reproductive and fertility health at three events throughout the year. During this event, women and their partners can learn more about their fertility during a short seminar about fertility basics and have blood drawn for a fertility test. The first event is being held on Thursday, April 10 at RMACTs Stamford office.

Knowledge is essential to fertility, says Dr. Spencer Richlin, a board-certified endocrinologist and partner with RMACT. Whether a woman chooses to start a family today or in the future, she should be making this decision with as much information as possible. An AMH test is a simple blood test that gives us great insight into a womans fertility and her family building options.

RMACTs Free Fertility Testing and Seminar Events are being held at three of RMACTs locations in Fairfield County:

Bipolar Disorder & Romantic Relationships (Video 2 of the Bipolar Blogs)

Posted in Bipolar Disorder by on the April 11, 2014
Tags: , , , , ,

0

Do you have a question you would like answered in my next video? Tell me here! http://liftweathernextvideo.webs.com/

Budget and Debt Counseling

Posted in Counseling by on the April 10, 2014
Tags: , ,

0

Budget and Debt Counseling

Do you have credit or debt issues? You are not alone. Money Management International offers free budget and debt counseling to those who need help with budge…
Video Rating: 3 / 5

New DePuy Hip Implant Lawsuit Alleges Pain and Suffering: Now, AttorneyOne Can Provide Advice

Posted in Counseling by on the April 9, 2014
Tags: , , , , , , , ,

0

San Diego, CA (PRWEB) April 03, 2014

AttorneyOne.com, a recognized authority on law, updated the website recently and, now, can actively provide an expert opinion in view of the recent news on DePuy Hip Replacement lawsuit and potential ASR Pinnacle Hip Recall lawsuit.

A new lawsuit was filed on March 4 by a man in West Virginia Northern District Court (case no. 3:2014cv00026) alleging that he experienced pain and suffering from his DePuy hip implant.

According to court documents, the next Case Management Conference in the DePuy ASR Multicounty Litigation is scheduled for April 9 (No. 293, Bergen County, Superior Court of New Jersey).

As mentioned in a new Case Management Order in the DePuy ASR Hip Impant Multidistrict Litigation, filed on January 31, all case-specific discovery obligations regarding plaintiff enrollment in US Settlement Program are stayed (MDL 2197, U.S. District Court for the Northern District of Ohio).

Taking into consideration the latest developments, AttorneyOne.com updated the website and, now, can actively provide an expert opinion including how to get in contact with legal counsel easily and inexpensively in cases of severe complications, allegedly from DePuy Hip Replacement. Sean Burke, director of Media Relations at AttorneyOne.com, adds that the relevant information illustrates that people continue to file DePuy Hip Replacement lawsuits. “For that reason,” he continues, “our focus should squarely fall on getting the word out and assisting people in finding the right legal assistance.

Data updated on March 13 by the Judicial Panel on Multidistrict Litigation indicate that there are more than 14,000 cases pending in the DePuy ASR & DePuy Pinnacle Multidistrict Litigations. More specifically, 8,622 cases concern the DePuy ASR Hip Implant Products Liability Litigation and 5,411 cases concern the DePuy Pinnacle Hip Implant Products Liability Litigation.

AttorneyOne.com has further information on DePuy Hip Replacement lawsuits including how to get in contact with legal counsel.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2014/04/prweb11730912.htm.







Greenberg Traurigs Jaret Davis Named to eMerge Americas Techweek100 Miami List, Recognized as Key Influencer in South Floridas Tech Ecosystem

0

MIAMI (PRWEB) April 01, 2014

Jaret L. Davis, Co-Managing Shareholder of the Miami office of the international law firm Greenberg Traurig, has been named to eMerge Americas inaugural Techweek 100 Miami list. Davis is recognized among the 100 local power players who demonstrate commitment to enabling innovation in South Floridas technology ecosystem and are significantly impacting the regions business and technology landscape.

The list, developed by the South Florida community and the Techweek team, includes managers of fast-growing technology companies, prominent investors, key enablers of the digital ecosystem, creators of new technologies, and other innovators and leaders. Techweek is a seven-day conference and expo where entrepreneurs, tech visionaries, and thought leaders meet to enable the innovation ecosystems in the key cities of Miami, Chicago, New York City, Los Angeles, and Detroit. Techweek recently partnered with eMerge Americas to host the inaugural eMerge Americas Techweek, slated for May 1-7 in Miami Beach. The conference aims to provide a forum for innovative thought exchange and transform Miami into the technological hub of the Americas.

Davis, who was recently recognized along with other Techweek100 honorees at a cocktail at Ocean House in Miami Beach, is a well-known leader and mentor in the South Florida startup community, particularly in the tech space. In addition to serving in official leadership capacities for organizations related to entrepreneurialism and technology, such as serving on the board of the SEED Foundation, as General Counsel to the Technology Foundation of the Americas, and as a mentor for the recent local TekFight forum for entrepreneurs, angel investors and inventors, Davis also mentors numerous local entrepreneurs and startups on an individual level.

At this important point in the evolution of the South Florida tech startup ecosystem, it is an honor to be named to eMerge Americas Techweek 100 alongside so many individuals driving growth and innovation in this burgeoning community, Davis said. I look forward to continuing to work together to establish South Florida as a national hub for technology, innovation and entrepreneurialism.

As Co-Managing Shareholder of Greenberg Traurigs Miami office, Davis oversees approximately 160 attorneys and 200 business staff based in the firms founding office. He also serves as a principal shareholder in the firms Corporate & Securities Practice, focusing on domestic and international transactions within the mergers and acquisitions, capital markets, and credit markets arenas representing companies with an industry focus on the IT, health care and biotech sectors.

Davis commitment to giving back is also evidenced by his deep involvement with community organizations. Currently, this includes serving as Vice Chairman of the Board of Directors of Miami Childrens Hospital, President of the University of Miami Law Alumni Association, member of the executive committee of the Beacon Council (Miamis economic development agency) and serving on numerous other philanthropic and civic boards, including organizations focused on supporting youths such as City Year.

About the Greenberg Traurig Miami office

The Greenberg Traurig Miami office, founded in 1967 by attorneys with a business-focused approach and a tradition of community service, has actively supported and helped drive South Florida’s growth as an international financial and cultural center and gateway between the United States, Latin America, Europe, the Middle East and Asia. The office is known for its Miami Roots, Global Reach. The attorneys advise local, national and international companies in numerous industries and sectors, including aviation, entertainment, financial institutions, health care, international trade and customs, manufacturing, real estate, retail and technology. In Florida, Greenberg Traurig serves clients from across seven offices in Boca Raton, Fort Lauderdale, Miami, Orlando, Tampa, Tallahassee and West Palm Beach.

About Greenberg Traurig, LLP

Greenberg Traurig, LLP is an international, multi-practice law firm with approximately 1750 attorneys serving clients from 36 offices in the United States, Latin America, Europe, the Middle East and Asia. Greenberg Traurig is among the Top 10 law firms on The National Law Journal’s 2013 NLJ 350, an annual ranking of the largest firms in the U.S. For additional information, please visit http://www.gtlaw.com.







DrugRisk Update: Studies Warn of Risperdal Side Affects in Children

Posted in Bipolar Disorder by on the April 6, 2014
Tags: , , , , , , ,

0

New York, NY (PRWEB) November 25, 2013

The medication safety advocates at DrugRisk.com are announcing updated information for parents whose children have been prescribed the antipsychotic drug Risperdal. A recent study shows higher risks of diabetes in children taking the drug*, in addition to prior concerns of abnormal breast growth**.

DrugRisk is a free resource providing the latest studies, warnings, recalls and legal news to those using popular prescription drugs. Patients can talk with their doctor about potential dangers, see if others are experiencing similar side effects and decide if they need legal advice.

Risperdal is an atypical antipsychotic drug from Johnson & Johnson subsidiary Janssen Pharmaceuticals approved to treat schizophrenia, bipolar disorder and autism. However, the company recently pled guilty to promoting it for unapproved treatments in hundreds of thousands of children***.

The resource center has added studies linking the drug to gynecomastia, or abnormal breast growth in children that can be accompanied by milk production**. As the condition is non-reversible, it often requires surgery to correct.

Now, DrugRisk has learned of a new study from Vanderbilt University which found antipsychotics like Risperdal may also triple the risk of type-2 diabetes in children*. The study followed more than 43,000 children, finding the risks may increase in just one year of use.

Johnson & Johnson has already paid settlements to patients filing a Risperdal lawsuit alleging they needed surgery after the drug caused abnormal breast growth****.

Anyone affected by diabetes or abnormal breast growth after taking Risperdal is urged to visit DrugRisk.com or speak with a lawyer about their legal options. However, due to the specialized nature of drug injury cases, DrugRisk only recommends lawyers who have already handled Risperdal lawsuits.

Visit http://www.DrugRisk.com today for more information on the research, side effects and litigation news related to Risperdal and other drugs, or to speak with a lawyer.

*Vanderbilt University Medical Center, 8/22/13; news.vanderbilt.edu/2013/08/antipsychotic-drug-use-in-children-for-moodbehavior-disorders-increases-type-2-diabetes-risk/

**Cedars-Sinai Division of Endocrinology, Sept. 2012; ncbi.nlm.nih.gov/pubmed/22862307

***Reuters, 11/4/13; reuters.com/article/2013/11/04/us-jnj-settlement-idUSBRE9A30MM20131104

****Bloomberg, 9/10/12; bloomberg.com/news/2012-09-10/j-j-settles-risperdal-lawsuit-on-opening-day-of-trial.html; Banks v. Janssen Pharmaceuticals, Philadelphia Court of Common Pleas, January Term 2010, No. 00618







Next Page »